A #MarchforScience participant talks about the need to stand up to anti-science policies, rhetoric
Without strong support for the sciences, our quest to transform basic research into meaningful new medicines will wither and die.
Without strong support for the sciences, our quest to transform basic research into meaningful new medicines will wither and die.
On Friday, GlaxoSmithKline's CEO of eight years, Andrew Witty, will formally retire and take a sliver of the proverbial glass ceiling with him. His replacement, Emma Walmsley, will be the first female head of a Big Pharma company.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Welcome to the senior VC club. Julie Sunderland of Biomatics Capital and Tracy Saxton of Pivotal bioVenture Partners closed their first funds this week, bringing fresh perspectives to the life science investment game.
Not surprising, but still dismal: A new Liftstream study of 177 publicly-listed biotechs found just 10.9 percent of board seats are occupied by women and just 8 percent had a female CEO.